 |
 |
 |
 |
 |
Subject: Adenosine Antagonist Reduces Off Time (AAN 2002) Date: 4/24/2002 E-MOVE reports from the 54th Annual Meeting of the American Academy of Neurology, April 13-20, in Denver Colorado. Poster numbers, session numbers, and pages are from Neurology 2002;58(supplement 7).1. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson’s disease with motor complications JP Hubble, R Hauser, Kyowa 6002-US-001 Study Group S21.001; A162 The adenosine A2a antagonist KW-6002 can reduce off time in advanced PD, according to this study. Eighty-three PD patients with motor complications were randomized to placebo, up to 20 mg/day KW-6002, or up to 40 mg/day KW-6002. Off time was assessed by patient home diary and by clinician score during an 8-hour clinic visit. Sixty-five patients completed the 12-week study, with equal withdrawal rates across treatment arms. Based on home diaries, treated patients had 1.7 hours less off time than placebo patients (p=0.004). Off-time reduction as measured by clinician rating approached statistical significance. No change was seen in dyskinesias. Adverse events were similar for treatment and placebo except for nausea and dizziness, which occurred in 28% and 13% of KW-6002 patients respectively, versus 7% and 3% of placebo patients. Supported by Kyowa Pharmaceuticals 2. Adenosine A2a antagonist treatment of Parkinson’s disease A Sherzai, W Bara-Jiminez, M Gillespie, A Favit, F Bibbiani, MJ Morris, MM Mouradian, T Chase P06.104; A467 In this placebo-controlled trial of 16 patients with advanced PD, KW-6002 was shown to potentiate the antiparkinsonian effects of levodopa and prolong its efficacy, but without increasing the dyskinetic effect. ---- 2002 E-MOVE conference reports are made possible in part through unrestricted educational grants from Elan Pharmaceuticals, Glaxo SmithKline, and Pharmacia Corporation. E-MOVE Editor: Richard Robinson, NASW, WE MOVE
|
|
| All contents copyright © WE MOVE 2010. This page last modified 2/25/2009. | |